[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"McGill University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":733},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,39,0,25,[9,51,77,98,134,169,202,231,258,287,315,341,367,398,421,442,484,512,536,564,593,620,652,677,702],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100627223","protecting-the-brain-from-post-stroke-cognitive-impairment-and-dementia-with-multimodal-exercise-training-100627223",false,"NCT07445841","Protecting the Brain From Post-Stroke Cognitive Impairment and Dementia With Multimodal Exercise Training","Protecting the Brain From Post-Stroke Cognitive Impairment and Dementia With Multimodal Exercise Training: A Bayesian Adaptive Trial (PROTECT)","PROTECT","Inclusion Criteria:\n\n* have had a first-ever ischemic\u002Fhemorrhagic stroke confirmed by MRI\u002FCT 0-6 months prior to participation.\n* Able to independently walk at least 10 meters (assistive devices permitted) and capable of following instructions will be required.\n\nExclusion Criteria:\n\n* Diagnosed with dementia\n* Medications that impact cognition\n* Absolute contraindications to exercise or MRI scanning\n* Significant disability (modified Rankin score \\>3)\n* Participants will be excluded if they have been engaged in a structured exercise training program outside their regular in\u002Fout-patient hospital rehabilitation since suffering the stroke.\n* Co-morbidities that preclude exercise participation, pain worsened with exercise, and communication (e.g., severe aphasia) or behavioral issues limiting safe participation will also be reasons for exclusion.","ALL","40 Years","80 Years",{"count":22,"type":23},120,"ESTIMATED","INTERVENTIONAL",[26],"NA","The rates of cognitive decline and dementia after stroke are disproportionately high. Strategies that can protect the brain early after the stroke event could reduce the future risk of cognitive decline and dementia in these patients. Although physical exercise is usually recommended after stroke, there is very little information about the protective effect of exercise implemented in early stages of recovery as a potential protective measure against cognitive decline and dementia risk in these patients. This study will investigate the effect of a multimodal exercise intervention implemented early after the stroke event on cognition and on a selected group of markers that can predict cognitive decline and dementia risk.",[29],"Stroke",[31,32,33,34,35,36,37],"multimodal exercise","cognition","blood brain barrier permeability","cerebral blood flow","inflammation","neurodegeneration","subacute stroke","RECRUITING","2026-06-28",{"date":41,"type":42},"2026-07-01","ACTUAL",{"date":44,"type":42},"2026-03-09",{"date":46,"type":23},"2030-12-31",{"name":48,"class":49},"McGill University","OTHER",2,{"id":52,"slug":53,"hasResults":12,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":65,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},"100641791","measuring-force-during-subpial-resection-procedure-using-a-novel-ex-vivo-calf-brain-model-with-integrated-sensor-100641791","NCT07650253","Measuring Force During Subpial Resection Procedure Using a Novel Ex Vivo Calf Brain Model With Integrated Sensor","Inclusion Criteria:\n\n* Right-handed medical students, neurosurgical residents, and staff neurosurgeons from McGill University\n\nExclusion Criteria:\n\n* Left-handed individuals",true,"18 Years",{"count":60,"type":23},9,"OBSERVATIONAL","Neurosurgery is a high-stakes surgical specialty where errors can result in significant morbidity. The amount of force applied simultaneously on the brain with multiple different instruments during complex neurosurgical procedures is a critical safety metric that, to the investigators' knowledge, has not been previously measured in a realistic operative environment.\n\nThe investigators have therefore developed a simulation platform integrating an ex vivo calf brain and a 3D-printed skull model attached to a force sensor capable of capturing real-time forces applied to the brain. A case series study will be conducted to evaluate the pattern of force applied. Medical students, neurosurgical residents, and staff neurosurgeons from McGill University will be recruited to perform subpial resections using our ex vivo calf brain simulation platform. The forces applied by the microscissors, bipolar forceps, and ultrasonic aspirator onto the brain will be captured. This study aims to demonstrate the spectrum of force applied during a neurosurgical procedure using an ex vivo calf brain model.",[64],"Surgical Education",[64,66,67],"Surgical Simulation","Force Measurement","2026-06-10",{"date":70,"type":42},"2026-06-16",{"date":72,"type":23},"2026-06",{"date":74,"type":23},"2026-07",{"name":48,"class":49},1,{"id":78,"slug":79,"hasResults":12,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":57,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":86,"conditions":87,"keywords":88,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":76},"100640232","validation-of-an-ex-vivo-calf-brain-force-detection-system-for-neurosurgical-simulation-training-100640232","NCT07583082","Validation of an Ex Vivo Calf Brain Force Detection System for Neurosurgical Simulation Training","Validation of an Ex Vivo Calf Brain Force Detection System for Neurosurgical Simulation Training: A Case Series Study","Inclusion Criteria:\n\n* Medical students, neurosurgical residents, neurosurgical fellows, and staff neurosurgeons from one of four Quebec institutions who do not fit the exclusion criteria.\n\nExclusion Criteria:\n\n* For medical students, participation in a previous trial where they received training on the NeuroVR surgical simulator or the ex vivo calf brain simulation model.",{"count":85,"type":23},30,"Neurosurgery is a high-stakes surgical specialty where errors can result in significant patient mortality and morbidity. The amount of force applied on the brain simultaneously by the multiple different instruments during complex neurosurgical procedures is a critical safety metric that, to the investigators' knowledge, has not been previously measured in a realistic operative environment.\n\nThe investigators have therefore developed a simulation platform integrating an ex vivo calf brain and a 3D-printed skull model attached to a force sensor capable of capturing real-time forces applied to the brain. A cross-sectional case series study will be conducted to evaluate the validity of the system. Medical students, neurosurgical residents, neurosurgical fellows, and staff neurosurgeons from four Quebec institutions will be recruited to perform three simulated subpial resections each using our ex vivo calf brain simulation platform. The forces applied by the microscissors, bipolar forceps, and ultrasonic aspirator onto the brain will be captured along with kinematic data. This study aims to establish the face, content, construct, and convergent validity of this ex vivo calf brain force detection system.",[64],[64,66],"NOT_YET_RECRUITING","2026-05-07",{"date":92,"type":42},"2026-05-13",{"date":94,"type":23},"2026-05",{"date":96,"type":23},"2026-09",{"name":48,"class":49},{"id":99,"slug":100,"hasResults":12,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":104,"eligibilityCriteria":105,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":106,"targetDuration":4,"studyType":24,"phases":108,"briefSummary":109,"conditions":110,"keywords":116,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":133},"100543973","evaluation-of-reacts-in-an-intervention-to-improve-nutrition-hygiene-and-sexual-and-reproductive-health-services-100543973","NCT06362837","Evaluation of REACTS-IN, an Intervention to Improve Nutrition, Hygiene, and Sexual and Reproductive Health Services","Realizing Gender Equality, Attitudinal Change & Transformative Systems in Nutrition (REACTS-IN)","REACTS-IN","Inclusion Criteria:\n\n(i)Women:\n\n* 15-49 y of age\n* biological mother of child in the home who is 0-5.9, 6-23.9, or 24-59.9 months\n* has lived in the community for at 12 months\n\n(ii) Husbands\u002Fpartners:\n\n* no age limit\n* lives in the home with index woman\n* has lived in community for at least 12 months\n\n(iii) Adolescents:\n\n* 10-19 years\n* male or female\n* has been in target school for at least 6 months\n* lives in the target community\n\n(iv) Children:\n\n* 0-5.9, 6-23.9, or 24-59.9 months\n\nExclusion Criteria:\n\n(i) Children:\n\n* no limitation on normal diet or growth (birth defects, illnesses)",{"count":107,"type":23},13500,[26],"This is an independent evaluation of World VIsion's 7-year quasi-experimental intervention to improve nutrition, nutrition-related rights and gender equality for women, adolescent girls, and children under five years of age in rural Bangladesh, Kenya, and Tanzania. The evaluation will collect baseline, midline, and end-line data from intervention communities, schools, and health facilities. Only baseline and endline will be collected on the comparison communities. The evaluation objectives are to test if the intervention improved indicators for (i) child anthropometry, (ii) maternal and child dietary practices, (iii) women's empowerment, and (iv) equitable health service access for nutrition and sexual and reproductive needs. The evaluation analysis will take into account gender differences in the indicators.",[111,112,113,114,115],"Stunting","Gender Equality","Acceptability of Health Care","Diet; Deficiency","Empowerment",[117,118,119,120,121,122,123,124],"nutrition","gender equity","health services","sexual and reproductive rights","dietary diversity","anthropometry","sexual and reproductive health services","WASH","2026-04-27",{"date":127,"type":42},"2026-04-29",{"date":129,"type":42},"2024-09-01",{"date":131,"type":23},"2029-12-31",{"name":48,"class":49},3,{"id":135,"slug":136,"hasResults":12,"nctId":137,"briefTitle":138,"officialTitle":139,"acronym":4,"eligibilityCriteria":140,"healthyVolunteers":57,"sex":18,"minAge":58,"maxAge":19,"enrollmentInfo":141,"targetDuration":4,"studyType":24,"phases":143,"briefSummary":144,"conditions":145,"keywords":149,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":161,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":76},"100569745","the-effects-of-cold-water-immersion-on-exercise-performance-recovery-and-postprandial-plasma-aminoacidemia-100569745","NCT06698237","The Effects of Cold-water Immersion on Exercise Performance Recovery and Postprandial Plasma Aminoacidemia","The Effects of Delayed Versus Immediate Cold-water Immersion on Exercise Performance Recovery and Postprandial Plasma Aminoacidemia Following Exercise and Protein Consumption in Athletes","Inclusion Criteria\n\nTo be eligible to participate in this study, a participant must meet all the following criteria:\n\n1. Healthy adult between 18 - 40 years (inclusive).\n2. Individual with a BMI between \\>18.5 and \\\u003C30 kg\u002Fm2 (inclusive).\n3. Individual who is in good general health (no uncontrolled diseases or conditions).\n4. individual with a history of regular resistance training ≥2 per week for the past six-months.\n5. Individual who is currently competing at the varsity, provincial, national or international level in their respective sport.\n6. Individual who is free from any musculoskeletal injuries and\u002For conditions that might affect their ability to perform resistance exercises or undergo cold-water immersion.\n7. Individual who has maintained stable use of medication and\u002For supplements, stable dietary and lifestyle habits, and stable body weight (weight loss or gain \\\u003C3 kg), for the last three-months prior to screening.\n8. Individual who agrees to maintain usual training habits between sessions.\n\nExclusion Criteria\n\n1. Individual who is lactating, pregnant or planning to become pregnant during the study.\n2. Females with irregular menstrual cycles (defined as outside 24-38 days cycle range, based on self-reports).\n3. Individual who adheres to a diet (e.g., vegan diet) that restricts consumption of dairy products.\n4. Has a known sensitivity, intolerability, or allergy to any of the study products or their excipients (i.e., lactose intolerant).\n5. Weight loss or gain \\> 3 kg in the 3 months prior to study visit 1.\n6. Currently or planning to be on a weight loss regimen during the study.\n7. Recent (within 2 weeks of screening visit) history of an episode of acute GI illness such as nausea\u002Fvomiting or diarrhea.\n8. Have a history of irritable bowel disease (IBS), inflammatory bowel disease (IBD, including ulcerative colitis and Crohn's disease), functional constipation or diarrhea (defined by the Rome IV diagnostic criteria), celiac disease, malabsorption, gastroparesis, diverticulosis, gastric or duodenal ulcers, pancreatitis, or eating disorder; or have a history of intestinal surgery (excluding appendectomy or herniorrhaphy) or bariatric surgery.\n9. Have an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and\u002For digestion (e.g., history of bowel obstruction).\n10. Participated in upper gastrointestinal endoscopy and\u002For colonoscopy or preparation within 3 months prior to screening visit.\n11. Diagnosed with hypercholesterolemia or hypertriglyceridemia (i.e., elevated fasting low- density lipoprotein (LDL) (≥ 135 mg·dL-1; ≥ 3.5 mmol·L-1) or elevated triglycerides (≥ 150 mg·dL-1; ≥1.7 mmol·L-1).\n12. Has a history of heart disease\u002Fcardiovascular disease, uncontrolled hypertension (≥ 140 systolic or ≥ 90 diastolic mmHg), kidney disease (dialysis or renal failure), hepatic impairment or disease.\n13. Is Type I or Type II diabetic or pre-diabetic \\[i.e., elevated fasting blood glucose levels (≥ 100 mg·dL-1; ≥ 5.6 mmol·L-1) and\u002For elevated hemoglobin A1c (≥ 6.0%)\\].\n14. Has a history of liver or gallbladder disease or stomach ulcers.\n15. Has a positive medical history of unstable thyroid disease, previously diagnosed major affective disorder, psychiatric disorder that required hospitalization in the prior year, immune disorders and\u002For immunocompromised (e.g., HIV\u002FAIDS).\n16. Diagnosed with cancer (except localized skin cancer without metastases or in situ cervical cancer) within 5 years prior to the screening visit, or any clinically significant disease or disorder which, in the opinion of the investigator, may either put the potential participant at risk because of participation in the study, or influences the results or the potential participant's ability to participate in the study.\n17. Major surgery in 3 months prior to screening or planned major surgery during the study.\n18. History of alcohol or substance abuse (including cannabinoids) in the 12 months prior to screening (including having been hospitalized for such in an in-patient or out-patient intervention program).\n19. Current or previous tobacco use within the last 6 months.\n20. Self-report of blood donation totaling between 101 mL to 449 mL of blood within 30 days prior to screening or a blood donation of more than 450 mL within 56 days prior to baseline.\n21. Self-report of donating plasma (e.g., plasmapheresis) within 14 days prior to screening.\n22. Any other active or unstable medical conditions or use of medications\u002Fsupplements\u002Ftherapies that, in the opinion of the investigator, may adversely affect the participant's ability to complete the study or its measures or pose a significant risk to the participant.",{"count":142,"type":23},12,[26],"In order to optimize sports performance, high-level athletes are required to manage conflicting training objectives, which often result in periods of high-volume training. These athletes need to perform heavy resistance training sessions to promote physiological adaptations, which consequently induce fatigue. Yet, they need to minimize fatigue to perform subsequent high-quality training sessions often within the same day. To support these training endeavours, a high-quality dietary regimen and adequate protein consumption is deemed to be an essential component of an athlete's recovery plan, as it has been shown to support muscle recovery and reduce muscle inflammation following exercise. Indeed, current sports nutrition recommendations advocate for the consumption of dietary protein and carbohydrate after exercise to promote tissue repair and replenish muscle energy stores (glycogen). Additionally, previous research has shown how water immersion therapies post-exercise may alleviate fatigue and restore performance. However, little is known about how different temperatures, as well as timing of cold-water immersion can support performance recovery in a population of athletes adhering to contemporary post-exercise nutrition recommendations. The objective of this project is to investigate the effects of timing of cold-water immersion relative to exercise on performance recovery within the same day, as well as to investigate whether cold water immersion augments blood amino acid concentrations after exercise and protein intake.",[146,147,148],"Sport Recovery","Aminoacidemia","Cold-water Immersion",[150,151,152,153,154,155,156,157,158,147,159,160],"Cold-water immersion","Protein","Performance","Athlete","Exercise physiology","Nutrition","Exercise","Resistance training","Sport recovery","cold-therapy","strength training","2026-04-07",{"date":163,"type":42},"2026-04-09",{"date":165,"type":42},"2024-12-20",{"date":167,"type":23},"2026-09-01",{"name":48,"class":49},{"id":170,"slug":171,"hasResults":12,"nctId":172,"briefTitle":173,"officialTitle":173,"acronym":174,"eligibilityCriteria":175,"healthyVolunteers":57,"sex":176,"minAge":58,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":24,"phases":179,"briefSummary":180,"conditions":181,"keywords":189,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":50},"100599326","enhancing-preschool-childrens-attention-and-behaviour-parent-focused-program-100599326","NCT07083037","Enhancing Preschool Children's Attention and Behaviour: Parent-Focused Program","BRIDGE-McGill","Inclusion Criteria:\n\nBRIDGE Therapy Group:\n\nParticipants are deemed eligible for the BRIDGE therapy group if they meet the following criteria:\n\n1. Above the age of 18.\n2. Self-identify as a mother of a child between the age of 3-7 years old.\n3. Currently living in Quebec, Ontario, or Manitoba\n4. Fluency in English.\n5. Mothers must have clinically significant symptoms of depression (mild to moderate on the Patient Health Questionnaire and indicate symptoms to \"somewhat cause difficulties\") currently affecting them. Participants also need to report symptoms of depression during pregnancy or shortly after birth.\n6. Their child has attention and\u002For behavior problems (T-score \\> 65 on the Child Behavior Checklist (CBCL) ADHD subscales) or confirmed attention and\u002For behavior problems through clinical interview.\n\nControl Group:\n\nParticipants are deemed eligible for the Control group if they meet the following criteria:\n\n1. Above the age of 18\n2. Self-identify as a mother of a child between the age of 3-7 years old\n3. Currently living in Quebec, Ontario, or Manitoba\n4. Fluency in English or bilingual\n5. Mothers must NOT have clinically significant symptoms of depression (mild to moderate on the Patient Health Questionnaire)\n6. Their child DOES NOT have attention and\u002For behavior problems (T-score \\> 65 on the Child Behavior Checklist (CBCL) ADHD subscales).\n\nExclusion Criteria:\n\nBRIDGE Therapy Group:\n\nParticipants were excluded if they A) did not meet the inclusion criteria listed above or B) were unable to attend the weekly BRIDGE group therapy sessions.\n\nFurthermore, eligible participants were invited to complete a semi-structured intake interview with principal investigator (PI) Dr. Tasmia Hai or a graduate student trainee under Dr. Hai's supervision, during which further questions about their mental health and child behavior were asked to ensure their eligibility. Based on the clinical suitability interview, participants may be excluded if they are deemed to be ineligible based on A) the mother's absence of clinically significant mental health symptoms, and\u002For B) the child's absence of attention and\u002For behavior problems. When relevant, participants may be identified to participate in the control group instead if eligibility is met.\n\nControl Group:\n\nParticipants were excluded if they did not meet the inclusion criteria listed above. Furthermore, eligible participants were invited to complete a semi-structured intake interview with principal investigator (PI) Dr. Tasmia Hai, during which further questions about their mental health and child behavior were asked to ensure their eligibility. Based on the clinical suitability interview, participants may be excluded if they are deemed to be ineligible based on a) the mother's presence of clinically significant mental health symptoms, and\u002For B) the child's presence of attention and\u002For behavior problems. When relevant, participants may be identified to participate in the BRIDGE therapy group instead if eligibility is met.","FEMALE",{"count":178,"type":23},60,[26],"This study aims to evaluate the feasibility and efficacy of the Building Regulation in Dual Generations (BRIDGE) program for caregivers with significant mental health concerns and preschool and young children (3-7 years old) with elevated attention and\u002For behavior problems. The BRIDGE program focuses on supporting parental psychological distress and improving young children's self-regulation (SR), thereby reducing their attention and behavior problems. The long-term goal of this work is to improve family well-being and social-emotional development for young children by implementing an accessible and scalable dual-regulation program. The investigators will achieve this through the following key objectives:\n\n1. Assess the feasibility and accessibility of BRIDGE for preschool and young children (3-7 years old) with significant attention and behavior programs through questionnaires asking about attendance, satisfaction, and unmet needs.\n2. Examine the efficacy of BRIDGE compared to control group at improving maternal mental health and child attention and behavioral difficulties in young children (primary outcomes). The investigators will also examine parenting stress (secondary outcome).\n3. Identify predictors of academic readiness skills in preschool and young children. The investigators hypothesize that an increase in parental and child emotion-regulation skills and reduced attention, as well as behavioral problems, will lead to increased pre-academic skills in children.",[182,183,184,185,186,187,188],"Maternal Depression","Self-Regulation, Emotion","Child Mental Disorder","Child Development","Attention Problems","Behaviour Problems","Parental Stress",[190,191,192,193],"maternal depression","child attention problems","child behaviour problems","parental stress","2026-04-02",{"date":196,"type":42},"2026-04-08",{"date":198,"type":42},"2025-02-01",{"date":200,"type":23},"2027-08-31",{"name":48,"class":49},{"id":203,"slug":204,"hasResults":12,"nctId":205,"briefTitle":206,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":57,"sex":18,"minAge":58,"maxAge":210,"enrollmentInfo":211,"targetDuration":4,"studyType":24,"phases":213,"briefSummary":214,"conditions":215,"keywords":217,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":76},"100631188","neuroimmune-responses-to-exercise-in-chronic-back-pain-100631188","NCT07497425","Neuroimmune Responses to Exercise in Chronic Back Pain","Neuroimmune Responses to Physical Exercise Training in Chronic Primary Low Back Pain","eCLBP","Inclusion Criteria-CLBP patients:\n\n* Have a diagnosis of chronic primary LBP, according to the criteria established by NIH Task Force on Research Standards for CLBP (Deyo et al., 2015). This will be determined by 1) the response to the National Institutes of Health minimum dataset for CLBP (NIH-md), including that LBP has been persistent for at least 3 months or recurrent for at least half of the days in the past 6 months, and 2) the results of a complete case history and physical examination (including functional tasks, quantitative sensory testing, and, if needed, neuro-orthopedic, palpation and range of motion assessments);\n* Report a CLBP intensity of at least 4 in a 0-10 numerical rating scale (0 = no pain, 10 = maximum possible pain).\n\nInclusion Criteria-Healthy controls:\n\n\\- Be over 18 years and under 75 years of age;\n\nExclusion Criteria-CLBP patients:\n\n* Present any red flags indicative of serious pathology comorbid or as the cause of CLBP (Finucane et al., 2020);\n* Have a CLBP phenotype characterized by predominant nociceptive (as in fracture, infection, malignancy, inflammatory or rheumatic spondyloarthropathy, cauda equina syndrome, confirmed by MRI when suspected) or neuropathic pain mechanisms, the latter assessed through score in the DN4 questionnaire (Nijs, et al., 2024);\n* Present chronic or acute pain of higher intensity or perceived disability in any other body site than the low back;\n* Medical history of diabetes, neurological or psychiatric disorder;\n* Presence of significant cardiorespiratory problems or any other potential contraindications to physical exercise as assessed through the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+);\n* Following a regular structured PE training program (\\>60 min\u002Fweek) at study's onset, and;\n* Presence of any contraindications to MRI examination (including any metallic implants or devices, being pregnant, and claustrophobia).\n\nExclusion criteria-Healthy controls:\n\n* Have symptoms or a diagnosis of any acute or chronic pain conditions;\n* Medical history of diabetes, neurological or psychiatric disorder;\n* Presence of significant cardiorespiratory problems or any other potential contraindications to physical exercise as assessed through the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+);\n* Following a regular structured PE training program (\\>60 min\u002Fweek) at study's onset, and;\n* Presence of any contraindications to MRI examination (including any metallic implants or devices, being pregnant, and claustrophobia).","75 Years",{"count":212,"type":23},216,[26],"The goal of this mechanistic clinical trial is to learn how physical exercise affects the body and brain in people with chronic low back pain. The study will examine whether a 12-week online exercise program changes these measures compared with a waitlist group. Researchers will also study immune activity and brain function in people with chronic low back pain and compare them with healthy participants. Participants will complete questionnaires, provide blood samples, and undergo brain imaging scans.",[216],"Chronic Low Back Pain (CLBP)",[218,219,35,220,221,222],"mechanisms","immune system","brain","chronic pain","exercise","2026-03-24",{"date":225,"type":42},"2026-03-27",{"date":227,"type":42},"2025-06-01",{"date":229,"type":23},"2029-06-30",{"name":48,"class":49},{"id":232,"slug":233,"hasResults":12,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":238,"enrollmentInfo":239,"targetDuration":4,"studyType":24,"phases":241,"briefSummary":242,"conditions":243,"keywords":244,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":76},"100608470","virtual-reality-for-post-stroke-gait-rehabilitation-100608470","NCT07201974","Virtual Reality for Post-Stroke Gait Rehabilitation","iWalk in VR: Integration of Virtual Reality-based Locomotor Rehabilitation in Clinical Care","Inclusion Criteria:\n\nEligible patients with stroke referred by clinicians of the inpatient and outpatient stroke rehabilitation programs at the Jewish Rehabilitation Hospital (CISSS Laval) for mobility problems over a period of 6 months will be recruited. They will:\n\n* be aged between 40 and 74 years;\n* have normal\u002Fcorrected visual and auditory acuity present;\n* present a first-ever supratentorial unilateral stroke of 1-24 weeks duration;\n* present the ability to walk independently with\u002Fwithout walking aids for at least 1 min at a speed of 0.4-0.9 m\u002Fs;\n* present intact or mildly affected cognitive function (MoCA scores ≥ 22\u002F30);\n* present intact to moderately affected visual- perceptual function (positive scores on a max. of 3\u002F6 tasks on the Behavioural Inattention Test).\n\nExclusion Criteria:\n\n* Subjects with comorbidities interfering with walking\n* Subjects with comorbidities interfering with visual perception\n* Subjects without medical clearance for exercise","84 Years",{"count":240,"type":23},40,[26],"The goal of this clinical trial is to: (1) implement and test the feasibility of a new VR-ODT intervention offered as part of usual therapy time of patients with a sub-acute stoke; (2) explore the acceptability of the intervention from the perspective of clinicians and patients and; (3) implement measures to optimize the uptake and sustainability of the intervention within the clinical setting.\n\nParticipants will engage in a personalized VR-ODT training for 4 weeks (2X 1hr\u002Fweek) targeting six well-established community walking demands related to (1) walking speed and (2) distance; (3) postural transitions; (4) obstacle avoidance; (5) dual-task walking and; (6) a combination of demands 1-5. For each demand, patients will progress through levels of increasing difficulty according to personalized goals and success criteria.",[29],[245,246,247,248,249],"Rehabilitation","Intervention","Community Walking","Virtual Reality","Clinical care","2026-03-17",{"date":252,"type":42},"2026-03-20",{"date":254,"type":42},"2026-02-01",{"date":256,"type":23},"2027-12",{"name":48,"class":49},{"id":259,"slug":260,"hasResults":12,"nctId":261,"briefTitle":262,"officialTitle":263,"acronym":4,"eligibilityCriteria":264,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":265,"targetDuration":4,"studyType":24,"phases":267,"briefSummary":268,"conditions":269,"keywords":271,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":133},"100488762","exercise-to-improve-sleep-in-parkinsons-disease-100488762","NCT05644327","Exercise to Improve Sleep in Parkinson's Disease","The Effects of Different Exercise Modalities on Sleep Quality and Architecture in People With Parkinson's Disease","Inclusion Criteria:\n\n* Persons with mild-moderate idiopathic Parkinson's Disease (Modified Hoehn \\& Yahr Scale stages 0.5-3.5);\n* On a stable dosage of medication during the previous month;\n* Having poor sleep quality defined as a score \\> 15 in the PDSS-2 and\u002For reporting subjective sleep complaints affecting their sleep quality;\n\nExclusion Criteria:\n\n* Having atypical parkinsonism, dementia, stroke, or any other neurological condition;\n* Presenting severe untreated obstructive sleep apnea (OSA);\n* Having a Montreal Cognitive Assessment (MoCA) score \\\u003C18\n* Having a Beck Depression Inventory score \\>31;\n* Having absolute contraindications to exercise;\n* Having severe osteoporosis;\n* Participating in an exercise or drug trial during the period of the study;\n* Exceeding the physical activity levels recommended for the general population (≥150 minutes\u002Fweek of moderate-intensity or ≥75 minutes\u002Fweek of vigorous-intensity cardiovascular activity) and\u002For strengthening activities ≥2 days\u002Fweek.",{"count":266,"type":23},150,[26],"This study will investigate the impact of three common exercise modalities, cardiovascular, resistance, and multimodal (i.e., a combination of the previous two) training, on sleep quality and architecture in persons with Parkinson's disease (PD). Furthermore, the project will investigate whether the potential positive exercise-induced changes in sleep are associated with improvements in different quality of life (QoL)-related aspects. Participants will perform either cardiovascular training (CT), resistance training (RT), multimodal training (MT), or will be allocated to a control condition (i.e., waiting list - CON) for 12 weeks. Training will be performed three times\u002Fweek. The assessments will be conducted at baseline, post-intervention, and follow-up (i.e. 8 weeks after the intervention) by assessors blinded to the participants' group allocation.",[270],"Parkinson Disease",[272,245,273,156,274,157,275,276,277,278],"Parkinson's disease","Sleep","Cardiovascular training","Multimodal training","Motor function","Cognition","Quality of life","2026-03-11",{"date":281,"type":42},"2026-03-13",{"date":283,"type":42},"2021-09-01",{"date":285,"type":23},"2027-12-30",{"name":48,"class":49},{"id":288,"slug":289,"hasResults":12,"nctId":290,"briefTitle":291,"officialTitle":291,"acronym":292,"eligibilityCriteria":293,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":294,"targetDuration":4,"studyType":24,"phases":295,"briefSummary":296,"conditions":297,"keywords":301,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":50},"100627376","the-pain-reduction-using-immersive-virtual-reality-during-wound-care-evaluation-study-at-maimonides-prism---pilot-study-100627376","NCT07447830","The Pain Reduction Using Immersive Virtual Reality During Wound Care Evaluation Study at Maimonides (PRISM) - Pilot Study","PRISM","Inclusion Criteria:\n\n* Resident of LTC for ≥2 weeks\n* Receiving regular wound care for pressure ulcers\n* Able to tolerate iVR headset use\n* (If cognitively apt) able to understand English or French\n\nExclusion Criteria:\n\n* Blindness, severe cataracts, or glaucoma\n* Allergies to synthetic plastics or headset materials\n* Head or ear wounds preventing headset placement\n* Peripheral neuropathy\n* Dangerous or aggressive behaviors in the past 30 days",{"count":7,"type":23},[26],"This study will test whether immersive virtual reality (iVR) can reduce pain and discomfort during wound care for residents living in long-term care (LTC). Pressure ulcers are common and painful among older adults, and dressing changes often cause additional distress.\n\nUp to 20 residents at the Donald Berman Maimonides Geriatric Centre will use virtual reality headsets during routine wound care. The headsets display calm, low-stimulus scenes (e.g., puppies in a meadow) designed to distract and comfort participants.\n\nEach participant will take part for six weeks in three phases:\n\n* Two weeks of usual wound care (baseline)\n* Two weeks using virtual reality during wound care (intervention)\n* Two weeks of usual care again (washout)\n\nPain will be assessed using validated tools, and the research team will also observe agitation, mood, and other behavioral indicators. Nursing staff will provide feedback on feasibility and acceptability of iVR use in LTC settings.",[298,299,300],"Wound Care","Pain","Neuropsychiatric Symptoms",[302,303,304,305,306],"immersive virtual reality","pain","wound care","depression","aggitation","2026-03-03",{"date":309,"type":42},"2026-03-05",{"date":311,"type":42},"2025-11-01",{"date":313,"type":23},"2027-04-15",{"name":48,"class":49},{"id":316,"slug":317,"hasResults":12,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":322,"enrollmentInfo":323,"targetDuration":4,"studyType":24,"phases":325,"briefSummary":326,"conditions":327,"keywords":328,"overallStatus":89,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":76},"100606667","feasibility-of-real-time-visual-feedback-in-augmented-reality-to-reduce-gait-asymmetry-post-stroke-100606667","NCT07178535","Feasibility of Real-Time Visual Feedback in Augmented Reality to Reduce Gait Asymmetry Post-Stroke","Feasibility of Two Types of Real-Time Visual Feedback in an Augmented Reality Environment to Reduce Spatial Gait Asymmetry in Adults Post-Stroke","Inclusion Criteria:\n\n* All participants must be in the subacute phase, between 14 days and 6 months following a first supratentorial stroke\n* able to walk with or without an assistive device for at least 2.5 minutes\n* present spatial asymmetry (step length ratio, SLR \\> 1.08)\n\nExclusion Criteria:\n\n* Abnormal or no-corrected visual acuity (EDTRS \\\u003C 50\u002F20)\n* visual field deficits (Goldmann or computerized perimetry)\n* cognitive impairment (Montreal Cognitive Assessment score \\\u003C 22\n* not being able to provide informed consent\n* present other conditions besides stroke that limit walking.","65 Years",{"count":324,"type":23},20,[26],"Unilateral motor deficits, such as paresis and tone disorders, are frequent consequences of stroke and lead to gait impairments. Among these, spatial asymmetry is characterized by differences in step length between the paretic and non-paretic limbs, resulting in balance problems and an increased risk of falls. Conventional rehabilitation has shown limited effectiveness in addressing this issue, highlighting the need for innovative approaches. Real-time feedback interventions, particularly through augmented reality (AR), may help improve gait asymmetry by providing a more natural and interactive learning environment.\n\nThis study aims to compare the effectiveness of two types of real-time visual feedback, an avatar-based system and visual bars, in improving gait symmetry and other locomotor parameters in individuals post-stroke. It will also assess the acceptability and usability of the intervention, participants' sense of presence, and the potential for cybersickness induced by these systems.\n\nA repeated-measures design will be used to evaluate the immediate effectiveness of the two types of visual feedback on gait asymmetry and other locomotor parameters in adults in the subacute phase after stroke. Participants, aged 18 to 65 and presenting spatial asymmetry, will perform walking trials in an AR environment while being exposed to both feedback modalities in randomized order. Spatiotemporal and kinematic data will be collected using inertial sensors, while questionnaires will assess acceptability, usability, sense of presence, and cybersickness.\n\nParticipants will be evaluated in a 45-m long corridor (free of traffic) and will perform nine walking trials (three per condition) under three randomized conditions: (1) a lateral view avatar displayed on the paretic side, previously shown to provide optimal feedback on step length; (2) a visual bar feedback representing bilateral step lengths; and (3) a \"control\" condition with no additional feedback. Each walking trial, lasting 2.5 minutes, will consist of a pre-adaptation phase without feedback (30 s), followed by an adaptation phase with feedback (1 min), and a post-adaptation phase without feedback (1 min).\n\nThe investigators expect that avatar-based feedback will be more effective than visual bars in improving spatial symmetry. The investigators also anticipate that both feedback modalities will be well accepted and usable by participants without inducing cybersickness, but that the sense of presence will be higher with avatar-based feedback. This study will shed light on locomotor adjustment mechanisms and may lay the groundwork for future clinical trials. By offering a personalized, evidence-based approach, these results could help transform post-stroke rehabilitation through the integration of innovative tools to optimize functional recovery.",[29],[329,330,331,332],"Post-stroke locomotor deficits","Spatial gait asymmetry","Real-time visual feedback","Augmented reality","2026-02-18",{"date":335,"type":42},"2026-02-19",{"date":337,"type":23},"2026-04-15",{"date":339,"type":23},"2027-09-15",{"name":48,"class":49},{"id":342,"slug":343,"hasResults":12,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":348,"enrollmentInfo":349,"targetDuration":4,"studyType":24,"phases":350,"briefSummary":351,"conditions":352,"keywords":353,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":360,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":50},"100405438","virtual-reality-and-field-training-to-enhance-community-walking-after-stroke-100405438","NCT04559373","Virtual Reality and Field Training to Enhance Community Walking After Stroke","A Virtual Reality and Field Training Toolkit to Enhance Community Ambulation and Participation in Stroke Survivors","Inclusion Criteria:\n\nPeople with chronic stroke and persistent deficits in walking \u002F visual-perceptual \u002F cognitive capacities. They can be male or female, aged from 40 to 74 years, with normal\u002Fcorrected visual and auditory acuity, and present with:\n\n* First-ever supratentorial unilateral stroke 9-24 months ago (such chronicity will ensure steady-state mobility without long-term disuse-related changes\n* Mild-to-moderate hemiparesis (Chedoke McMaster Stoke Assessment stages 4\u002F7-6\u002F7 on postural control, leg \\& foot)\n* Ability to walk independently with\u002Fwithout walking aids for at least 1 min at 0.4-0.9 m\u002Fs (such a speed range indicates mobility not sufficient for functional community ambulation: shopping \\~1.1m\u002Fs, street crossing \\~1.2 m\u002Fs)\n* Intact or mildly affected cognitive function (Montreal Cognitive Assessment scores ≥ 22\u002F30)\n* Intact to moderately affected visual-perceptual function (positive scores on a maximum of 3\u002F6 tasks on the Behavioural Inattention Test)\n\nExclusion Criteria:\n\n* Subjects with comorbidities interfering with walking\n* Subjects with comorbidities interfering with visual perception\n* Subjects without medical clearance for exercise","74 Years",{"count":240,"type":23},[26],"While stroke survivors discharged from rehabilitation present with some recovery in mobility, their ability to ambulate in the community remains limited. The investigators propose to test a novel, low-cost, intensive and individually tailored intervention that combines virtual reality (VR) and field training to enhance community ambulation and participation in stroke survivors discharged from rehabilitation.\n\nThe aims are to: (1) Assess feasibility, acceptability, safety and adherence of the intervention in stroke survivors; and (2) Examine the extent to which post-intervention changes in functional walking and participation to community walking vary according to walking, cognitive and visual-perceptual abilities.\n\nThe investigators will use a virtual environment prototype simulating a shopping mall and surrounding streets, in which participants will interact using VR goggles and game controllers. Scenarios of increasing levels of complexity will be introduced. This intervention study involves a single group, multiple pre- multiple post- study design where chronic stroke participants will engage in a 4-week training program. The program will include VR training sessions performed in the clinical setting (3\u002Fweek) and practice of community ambulation skills while supervised by family\u002Fcaregivers (2\u002Fweek). Participants will be assessed on measures of functional walking, balance \\& mobility and participation to community walking. Adherence, safety and acceptability will be documented. This study will generate foundation knowledge on the response to the intervention based on individual capacities.",[29],[354,355,356,246,357,245,358,359],"Aging","Biomechanics","Community ambulation","Locomotion","Sensorimotor integration","Virtual reality",{"date":361,"type":42},"2026-02-20",{"date":363,"type":42},"2021-04-01",{"date":365,"type":23},"2026-12-31",{"name":48,"class":49},{"id":368,"slug":369,"hasResults":12,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":4,"eligibilityCriteria":373,"healthyVolunteers":57,"sex":18,"minAge":374,"maxAge":375,"enrollmentInfo":376,"targetDuration":4,"studyType":24,"phases":378,"briefSummary":379,"conditions":380,"keywords":383,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":391,"startDateStruct":393,"completionDateStruct":395,"leadSponsor":397,"locationsCount":76},"100603897","effects-of-omeprazole-ingestion-on-postprandial-amino-acid-concentrations-in-response-to-a-mixed-meal-100603897","NCT07142486","Effects of Omeprazole Ingestion on Postprandial Amino Acid Concentrations in Response to a Mixed Meal","Effects of Omeprazole Ingestion on Postprandial Amino Acid Concentrations in Response to a Mixed Meal: A Pilot Study","Inclusion Criteria:\n\n1. Healthy adult female or male participants who are 50 to 60 years of age at screening (inclusive)\n2. Has a BMI between 18.5 to 29.9 kg·m-2 (inclusive) at screening visit\n3. In good general health (no uncontrolled diseases or conditions) as deemed by the investigator and able to consume the study product\n4. Has maintained stable use of medication and supplements stable dietary and lifestyle habits, and stable body weight, for the last 3 months prior to screening and agree to maintain them throughout the study\n5. Agree to avoid strenuous exercise 48 h prior to each study visit\n6. Willing to limit daily alcohol consumption to no more than 3 standard drinks per day throughout the study, and agree to entirely avoid alcohol consumption 48 h prior to each visit (a standard serving is defined here as 4 oz wine, 12 oz beer, 1 oz spirits)\n7. Willing to maintain current use of cannabinoids (if applicable) throughout the study\n8. Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, and carry out all study-related procedures.\n\nExclusion Criteria:\n\n1. Individuals who are lactating, pregnant or planning to become pregnant during the study\n2. Individuals who adhere to a diet (e.g., vegan diet) that restricts consumption of dairy products\n3. Has a known sensitivity, intolerability, or allergy to any of the study products or their excipients (i.e., lactose intolerant)\n4. Weight loss or gain \\> 3 kg in the 3 months prior to study visit 1\n5. Currently or planning to be on a weight loss regimen during the study\n6. Received a vaccine for COVID-19 in the two weeks prior to screening or plans to receive a vaccine for COVID-19 during the study period, currently has COVID-19 or tests positive for COVID-19 within 28 days prior to baseline visit, or currently has any post COVID-19 condition(s) as defined by World Health Organization (WHO) (i.e., individuals with a history of probable or confirmed SARS-CoV-2 infection, usually three months from the onset of COVID-19 with symptoms that last for at least 2 months and cannot be explained by an alternative diagnosis)\n7. Recent (within 2 weeks of screening visit) history of an episode of acute GI illness such as nausea\u002Fvomiting or diarrhea\n8. Have a history of irritable bowel syndrome (IBS), inflammatory bowel disease (IBD, including ulcerative colitis and Crohn's disease), functional constipation or diarrhea (defined by the Rome IV diagnostic criteria), celiac disease, malabsorption, gastroparesis, diverticulosis, gastric or duodenal ulcers, pancreatitis, or eating disorder; or have a history of intestinal surgery (excluding appendectomy or herniorrhaphy) or bariatric surgery\n9. Have an abnormality or obstruction of the gastrointestinal tract precluding swallowing (e.g., dysphagia) and\u002For digestion (e.g., history of bowel obstruction)\n10. Participated in upper gastrointestinal endoscopy and\u002For colonoscopy or preparation within 3 months prior to screening visit\n11. Diagnosed with hypercholesterolemia or hypertriglyceridemia (i.e., elevated fasting low-density lipoprotein (LDL) (≥ 135 mg·dL-1; ≥ 3.5 mmol·L-1) or elevated triglycerides (≥ 150 mg·dL-1; ≥1.7 mmol·L-1)\n12. Has a history of heart disease\u002Fcardiovascular disease, uncontrolled hypertension (≥ 140 systolic or ≥ 90 diastolic mmHg), kidney disease (dialysis or renal failure), hepatic impairment or disease\n13. Is Type I or Type II diabetic or pre-diabetic \\[i.e., elevated fasting blood glucose levels (≥ 100 mg·dL-1; ≥ 5.6 mmol·L-1) and\u002For elevated hemoglobin A1c (≥ 6.0%)\\]\n14. Has a history of liver or gallbladder disease or stomach ulcers\n15. Has a positive medical history of unstable thyroid disease, previously diagnosed major affective disorder, psychiatric disorder that required hospitalization in the prior year, immune disorders and\u002For immunocompromised (e.g., HIV\u002FAIDS)\n16. Diagnosed with cancer (except localized skin cancer without metastases or in situ cervical cancer) within 5 years prior to the screening visit, or any clinically significant disease or disorder which, in the opinion of the investigator, may either put the potential participant at risk because of participation in the study, or influences the results or the potential participant's ability to participate in the study\n17. Major surgery in 3 months prior to screening or planned major surgery during the study\n18. History of alcohol or substance abuse (including cannabinoids) in the 12 months prior to screening (including having been hospitalized for such in an in-patient or out-patient intervention program)\n19. Receipt or use of test products in another research study within 30 days prior to study visit 1 or longer if the previous test product is deemed by the investigator to have lasting effects that might influence the eligibility criteria or outcomes of the current study\n20. Current or previous tobacco use within the last 6 months\n21. Self-report of blood donation totaling between 101 mL to 449 mL of blood within 30 days prior to screening or a blood donation of more than 450 mL within 56 days prior to baseline\n22. Self-report of donating plasma (e.g., plasmapheresis) within 14 days prior to screening.\n23. Any other active or unstable medical conditions or use of medications, supplements, or therapies that, in the opinion of the investigator, may adversely affect the participant's ability to complete the study or its measures or pose a significant risk to the participant.","50 Years","60 Years",{"count":377,"type":23},4,[26],"Omeprazole is a proton pump inhibitor commonly used to reduce stomach acid in the treatment of heartburn, gastroesophageal reflux disease, and gastric ulcers. By blocking the H⁺\u002FK⁺-ATPase pumps in the gastric lining, it raises gastric pH and can alter the normal activation of pepsin, the enzyme responsible for beginning protein breakdown in the stomach.\n\nUnder normal conditions, dietary proteins are denatured by gastric acid and cleaved by pepsin into smaller peptides. These peptides enter the small intestine, where pancreatic enzymes (trypsin, chymotrypsin) and brush-border peptidases (aminopeptidase, dipeptidase) further hydrolyze them into free amino acids that are absorbed into the bloodstream. Suppressing stomach acidity may allow larger peptides to pass into the intestine, potentially reducing the efficiency of amino acid liberation and absorption.\n\nIn this randomized, crossover study, adults aged 50-60 years will attend two study visits at least one week apart. In one visit they will take a standard dose of omeprazole before consuming a mixed meal with a fixed protein content; in the other visit they will consume the same meal without medication. Blood samples will be collected before the meal and at multiple time points afterward to measure plasma amino acid concentrations and compare postprandial responses.\n\nOlder adults experience anabolic resistance, meaning they require higher protein intakes to stimulate muscle protein synthesis effectively. If omeprazole reduces amino acid availability after a meal, individuals taking this medication may need adjusted dietary protein recommendations. Findings from this study will help refine nutrition guidelines for people on proton pump inhibitors and support optimal muscle health and recovery in middle-aged and older adults.",[381,382],"Digestive Health","Gastrointestinal Health",[147,384,385,386,387,151,388,389],"Omeprazole","Mixed Meal","Healthy Adults","Postprandial","Proton Pump Inhibitor","PPI","2026-02-05",{"date":392,"type":42},"2026-02-06",{"date":394,"type":42},"2025-09-01",{"date":396,"type":23},"2026-03",{"name":48,"class":49},{"id":399,"slug":400,"hasResults":12,"nctId":401,"briefTitle":402,"officialTitle":402,"acronym":403,"eligibilityCriteria":404,"healthyVolunteers":12,"sex":18,"minAge":405,"maxAge":375,"enrollmentInfo":406,"targetDuration":4,"studyType":24,"phases":408,"briefSummary":409,"conditions":410,"keywords":412,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":416,"startDateStruct":417,"completionDateStruct":419,"leadSponsor":420,"locationsCount":50},"100576448","dietary-protein-requirements-in-adults-with-facioscapulohumeral-muscular-dystrophy-100576448","NCT06785428","Dietary Protein Requirements in Adults With Facioscapulohumeral Muscular Dystrophy","FSHD","Inclusion Criteria:\n\n* Adult female or male participants who are 26 to 60 years of age at screening (inclusive)\n* Genetically confirmed with FSHD\n* Ambulatory\n* Has maintained stable use of medication and supplements, stable dietary and lifestyle habits, and stable body weight, for the last 3 months prior to screening and agree to maintain them throughout the study\n* Willing and able to agree to the requirements and restrictions of this study, be willing to give voluntary consent, be able to understand and read the questionnaires, and carry out all study-related procedures\n\nExclusion Criteria:\n\n* Individuals who are lactating or pregnant\n* Usage of corticosteroids within 3 months of study entry or had ever taken steroids for a duration exceeding 1 year\n* On androgens or growth hormone within 6 months before screening and for duration of study; topical physiologic androgen replacement is permitted\n* On sympathomimetic agents, antidepressants, or β-receptor blockers\n* Have cardiovascular disease\n* Evidence of an alternative diagnosis other than FSHD or a coexisting myopathy or dystrophy\n* Current\u002Factive malignancy (e.g., remission less than 5 years' duration), with the exception of fully excised or treated basal cell carcinoma, cervical carcinoma in-situ, or ≤ 2 squamous cell carcinomas of the skin\n* Type 1 or type 2 diabetes mellitus\n* History of sensitivity to protein pharmaceuticals\n* Known active substance abuse, including alcohol\n* Renal impairment (serum creatinine ≥ 2 times the upper limit of normal,(ULN))\n* History of severe restrictive or obstructive lung disease, or evidence for interstitial lung disease on screening chest radiograph\n* Major surgery within 4 weeks prior to metabolic trial 1\n* Any other active or unstable medical\u002Fpsychological conditions or use of medications\u002Fsupplements\u002Ftherapies that, in the opinion of the investigator, may adversely affect the participant's ability to complete the study or its measures or pose a significant risk to the participant.","26 Years",{"count":407,"type":23},10,[26],"Facioscapulohumeral muscular dystrophy (FSHD) is one of the most common types of muscular dystrophy, affecting about 4 out of 100,000 individuals. The disease is characterized by progressive muscle loss (i.e., muscle atrophy) commonly affecting the face, shoulders, and upper arm muscles. The muscle loss ultimately results in reduced strength and impaired physical performance. At present there is no cure for FSHD, therefore, physicians have focused on therapeutic interventions to help alleviate these symptoms.\n\nDaily consumption of adequate amounts of dietary protein is essential to support muscle mass maintenance and overall health and function across the lifespan. However, previous research has reported inadequate protein intake in individuals with FSHD. The characteristic of progressive muscle loss in individuals with FSHD and other muscular dystrophies is ultimately due to an imbalance in the rate of muscle building (i.e., muscle protein synthesis) and muscle breakdown (i.e., muscle protein breakdown), where individuals with FSHD have been shown to have reduced rates of muscle building. As inadequate protein intake is known to result in a loss of muscle mass, strength and function, this loss may be amplified in individuals with FSHD.\n\nDietary recommendations traditionally have been determined through nitrogen balance techniques, where the current recommended dietary allowance (RDA) for daily protein intake for adults is 0.8 g\u002Fkg\u002Fd. However, recent research indicates how the nitrogen balance technique potentially underestimates protein requirements. Therefore, there is a need to reassess current dietary recommendations in adults with FSHD in order to help support the maintenance of muscle strength and function.\n\nRecent efforts to understand protein requirements in various populations have been completed using the indicator amino acid oxidation technique (IAAO). This non-invasive method is reported to provide a robust measure of protein requirements. Due to its non-invasive nature, the IAAO method allows researchers to use this technique in individuals with FSHD, where there is currently limited work in studying this population.\n\nThe purpose of this study is to measure the protein requirements in individuals with FSHD using the non-invasive IAAO technique.",[411],"Fascioscapulohumeral Muscular Dystrophy",[413,414,415],"Protein requirements","Facioscapulohumeral muscular dystrophy","Indicator amino acid oxidation technique",{"date":392,"type":42},{"date":418,"type":42},"2025-01-19",{"date":396,"type":23},{"name":48,"class":49},{"id":422,"slug":423,"hasResults":12,"nctId":424,"briefTitle":425,"officialTitle":425,"acronym":4,"eligibilityCriteria":426,"healthyVolunteers":57,"sex":427,"minAge":322,"maxAge":4,"enrollmentInfo":428,"targetDuration":4,"studyType":24,"phases":430,"briefSummary":431,"conditions":432,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":390,"lastUpdatePostDateStruct":436,"startDateStruct":438,"completionDateStruct":440,"leadSponsor":441,"locationsCount":76},"100549232","protein-requirements-amongst-male-masters-level-athletes-following-a-cycling-exercise-bout-as-determined-by-the-indicator-amino-acid-oxidation-technique-100549232","NCT06431334","Protein Requirements Amongst Male Masters-Level Athletes Following a Cycling Exercise Bout as Determined by the Indicator Amino Acid Oxidation Technique","Inclusion Criteria:\n\n* 18.5\\\u003C BMI \\\u003C35 kg\u002Fm\\^2\n* Overtly healthy masters level cyclists ≥65 years\n* Masters level cyclist training (\\>4 days per week; \\~100 km per week)\n* Body mass stable over previous 6-months\n* Availability for multiple metabolic trials (\\~7 trials)\n* Ability to travel to and from laboratory facility\n\nExclusion Criteria:\n\n* Recent history of weight loss or weight gain (\\>5% body weight)\n* Uncontrolled hypertension\n* ≥2 chronic diseases (e.g. diabetes, osteoporosis, dyslipidemia)\n* Acute illness that could affect protein metabolism (HIV, renal dysfunction, influenza)\n* Currently using anti-inflammatory medications\n* Inability to adhere to study protocol (i.e., alcohol, caffeine, dietary restrictions)\n* Regular tobacco user\n* Illicit drug use\n* Habitually ingesting ≥3 g\u002Fkg\u002Fbw","MALE",{"count":429,"type":23},8,[26],"Masters level cyclists are a population above the age of 35 years who frequently participate in prolonged as well as heavy-volume training. Like most endurance-trained athletes, a greater recommended dietary allowance (RDA) for protein of 1.2-1.4 g\u002Fkg\u002Fbw is suggested.\n\nDietary protein intake is vital for maximizing the benefits of training and ensuring optimal recovery. Dietary recommendations traditionally have been determined through nitrogen balance techniques, however, recent research indicates how this method is potentially underestimating protein requirements. Therefore, there is a need to reassess current dietary recommendations in order to meet the demands of physical activity for highly active populations.\n\nRecent efforts to understand protein requirements during rest and following exercise have been completed using the indicator amino acid technique (IAAO). This non-invasive method is reported to provide a robust measure of protein requirements. However, there is limited work in older (≥60 years) active populations.\n\nThe purpose of this study is to measure the protein requirements in master cyclists, following an endurance training session, using the non-invasive IAAO technique.",[433,434,435],"Healthy","Increased Metabolic Requirements","Dietary Reference Intakes",{"date":437,"type":42},"2026-02-09",{"date":439,"type":42},"2024-06-21",{"date":72,"type":23},{"name":48,"class":49},{"id":443,"slug":444,"hasResults":12,"nctId":445,"briefTitle":446,"officialTitle":447,"acronym":448,"eligibilityCriteria":449,"healthyVolunteers":57,"sex":18,"minAge":374,"maxAge":450,"enrollmentInfo":451,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":453,"conditions":454,"keywords":465,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":480,"leadSponsor":482,"locationsCount":483},"100316694","comprehensive-assessment-of-neurodegeneration-and-dementia-100316694","NCT03402919","Comprehensive Assessment of Neurodegeneration and Dementia","The Comprehensive Assessment of Neurodegeneration and Dementia Study","COMPASS-ND","Inclusion Criteria:\n\n* Has subjective or objective cognitive impairment\n* Written informed consent must be obtained and documented (from the patient or, where jurisdictions allow it, from a caregiver\u002Ffamily member)\n* Sufficient proficiency in English or French to undertake self report and neuropsychological testing\n* Geographic accessibility to the study site\n* Must have a study partner who can participate as required in the protocol (provide corroborative information)\n* Up to 12 years of education\n* Fits into one of the following groups: Cognitively Unimpaired, Subjective Cognitive Impairment, Mild Cognitive Impairment, Vascular Mild Cognitive Impairment, Parkinson's Disease, Parkinson's Disease with Mild Cognitive Impairment\n\nExclusion Criteria:\n\n* The presence of other significant known chronic brain disease such as: moderate to severe chronic static leukoencephalopathy (including previous traumatic injury), multiple sclerosis, a serious developmental handicap, malignant tumors, Parkinson's disease (other than for the Parkinson's cohort), and other rarer brain illnesses\n* Ongoing alcohol or drug abuse which in the opinion of the investigator may interfere with the subject's ability to comply with the study procedures\n* Symptomatic stroke within the previous year\n* Unable to undergo MRI scan due to medical contraindications or inability to tolerate the procedure","90 Years",{"count":452,"type":23},1573,"This is a longitudinal observational study recruiting individuals between the ages of 50 and 90 with different types of dementia as well as a comparison group without cognitive deficits. Participants are\u002Fwill be recruited at sites across Canada and will undergo assessments, neuroimaging, and biological sample collection.",[455,456,457,458,459,460,461,462,463,464],"Dementia","Mild Cognitive Impairment (MCI)","Subjective Cognitive Impairment","Parkinson's Disease (PD)","Lewy Body Disease(LBD)","Mixed Dementia","Frontotemporal Dementia (FTD)","Alzheimer Disease (AD)","Cognitively Unimpaired","Subjective Cognitive Decline (SCD)",[466,455,467,468,469,470,471,472,473,474],"Observational","Alzheimer's Disease","Parkinson's Disease","Biosample","Genetics","Neuropsychological","MRI","Microbiome","Plasma","2026-01-15",{"date":477,"type":42},"2026-01-20",{"date":479,"type":42},"2016-06",{"date":481,"type":23},"2029-12",{"name":48,"class":49},19,{"id":485,"slug":486,"hasResults":12,"nctId":487,"briefTitle":488,"officialTitle":488,"acronym":4,"eligibilityCriteria":489,"healthyVolunteers":57,"sex":18,"minAge":490,"maxAge":4,"enrollmentInfo":491,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":493,"conditions":494,"keywords":501,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":76},"100619731","the-diabeat-study-insulin-delivery-technologies-and-eating-behaviours-in-people-with-type-1-diabetes-100619731","NCT07348432","The diabEAT Study: Insulin dElivery Technologies And eaTing Behaviours in People With Type 1 Diabetes","Inclusion Criteria:\n\n* 12 years of age or older\n* Living in Canada\n* Living with type 1 diabetes for more than 1 year\n* Using at least 2 insulin injections per day or using an insulin pump\n* Using current insulin delivery system for 3 months or more\n\nExclusion Criteria:\n\n* Are pregnant or currently are breastfeeding\n* Don't speak French or English\n* Does not have a smart phone (to download applications)","12 Years",{"count":492,"type":23},106,"Type 1 diabetes is an autoimmune health condition that requires daily injections of insulin. Insulin allows the body to use energy from carbohydrates in food. Disordered eating behaviours, like restricting food intake to lose body weight, are more common in women and people with type 1 diabetes, compared to those without because they must practice carbohydrate counting. Carbohydrate counting means identifying, measuring, and planning carbohydrate intake to match insulin dosage. New technologies, such as automated insulin delivery (AID) systems adjust insulin delivery in a blood sugar responsive manner. AID is rapidly replacing conventional insulin delivery like injections or non-automated insulin pumps since it reduces management burden and improves blood sugar levels. It is not known if AID reduces food management and disordered eating behaviours. This study aims to: 1. investigate the relationship between AID and eating behaviours according to gender for youth (12 to 17 years), and adults (18 years and older). 2. Determine the limit of carbohydrate counting inaccuracy to maintain stable blood sugar levels according to insulin delivery method (AID, injections, or pumps). It is hypothesized that those who use AID will have lower disordered eating behaviours and will maintain stable blood sugar levels while allowing for higher carbohydrate counting inaccuracy. This will be a cross-sectional cohort study of people with type 1 diabetes who are 12 years of age or over. Participants will be recruited through the BETTER registry and social medias across Canada. This research is needed to improve nutrition guidelines for type 1 diabetes in the context of new technologies like AID. Evidence from this study may reduce food management burden, lower the risk of disordered eating behaviours, and prevent eating disorders and medical complications.",[495,496,497,498,499,500],"Insulin Dependent Diabetes Mellitus","Feeding and Eating Disorders","Eating Behavior","Type 1 Diabetes","Autoimmune Diseases","Endocrine System Diseases",[502,503,155,498],"Automated Insulin Delivery","Disordered Eating Behaviours","2026-01-12",{"date":506,"type":42},"2026-01-16",{"date":508,"type":42},"2024-07-29",{"date":510,"type":23},"2026-05-01",{"name":48,"class":49},{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":4,"eligibilityCriteria":518,"healthyVolunteers":12,"sex":18,"minAge":374,"maxAge":4,"enrollmentInfo":519,"targetDuration":4,"studyType":24,"phases":521,"briefSummary":522,"conditions":523,"keywords":525,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":530,"lastUpdatePostDateStruct":531,"startDateStruct":532,"completionDateStruct":534,"leadSponsor":535,"locationsCount":76},"100619931","understanding-how-movements-are-transferred-from-task-to-task-in-parkinsons-disease-100619931","NCT07351032","Understanding How Movements Are Transferred From Task to Task in Parkinson's Disease","Neural Mechanism of Skill Transfer in Parkinson's Disease","Inclusion Criteria:\n\n* a confirmed diagnosis of idiopathic Parkinson's disease\n* absence of freezing of gait confirmed by a \"No\" answer to the second item of the New Freezing of Gait Questionnaire (NFOGQ) and no observation of FOG during a freezing provoking test\n* no other neurological diagnosis\n* no severe musculoskeletal\u002Forthopedic or vestibular condition that interferes with walking and or significantly affects balance\n* no mild cognitive impairment (Montreal Cognitive Assessment ≥ 25)\n* able to walk independently and without assistive device for 30 minutes\n* no previous experience with split-belt treadmill.\n\nExclusion Criteria:\n\n* severe dyskinesia that interacts with walking and balance hearing or visual impairment\n* observed inability to walk safely on a tied-belt treadmill\n* neurological disorders other than PD or other pathology (e.g., orthopedic) interfering with mobility. - contradiction for TMS\n* implanted deep brain stimulator.",{"count":520,"type":23},24,[26],"The purpose of this study is to understand how a specific brain area, the Posterior Parietal Cortex (PPC), plays a role in movement transfer from walking on a split-belt treadmill (SBT) to walking on the ground in people with Parkinson's disease (PwPD).\n\nHere, investigators will apply repeated transcranial magnetic stimulation (rTMS) to upregulate the PPC. Then, the differences in the gait parameters between pre- and post-interventions will be compared between the TMS-active and the TMS-sham.",[524],"PARKINSON DISEASE (Disorder)",[526,527,528,529],"Transcranial Magnetic Stimulation","Split-belt Treadmill","Gait","Motor Adaptation","2026-01-09",{"date":477,"type":42},{"date":533,"type":42},"2025-11-18",{"date":94,"type":23},{"name":48,"class":49},{"id":537,"slug":538,"hasResults":12,"nctId":539,"briefTitle":540,"officialTitle":540,"acronym":4,"eligibilityCriteria":541,"healthyVolunteers":12,"sex":176,"minAge":58,"maxAge":4,"enrollmentInfo":542,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":543,"conditions":544,"keywords":546,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":556,"lastUpdatePostDateStruct":557,"startDateStruct":559,"completionDateStruct":561,"leadSponsor":563,"locationsCount":76},"100382347","doveegene-fleur-new-uterine-sampling-tool-100382347","NCT04258449","DOvEEgene Fleur: New Uterine Sampling Tool","Inclusion Criteria:\n\n* Be at least 18 years of age.\n* Have capacity to understand the study.\n* Be able to provide informed consent.\n* If the patient has a recently treated cervical abnormality, she must have had a Pap smear with normal results at least 4 months following treatment by loop electrosurgical excision procedure (LEEP) or cone biopsy.\n* Have suspected or confirmed cancer of the upper genital tract and be undergoing surgery for said tumor removal.\n\nExclusion Criteria:\n\n* Prior hysterectomy.\n* Be pregnant or possibly pregnant.\n* Be nursing, as the device contains phthalates (plasticizers) that \"have not been fully characterized and there may be concern for reproductive and developmental effects\".\n* Have an infected or inflamed cervix.\n* Have a confirmed or suspected pelvic infection.\n* Have a confirmed or suspected vaginal infection.\n* Have had recent history of uterine perforation.\n* Patients with recently treated cervical abnormalities must have a Pap smear with normal results at least 4 months following treatment by loop electrosurgical excision procedure (LEEP) or cone biopsy in order to be eligible.",{"count":240,"type":23},"This study is related to a previous study from the same group which started in 2014 (NTC02288676, McGill REB A08-M79-13B, MUHC REB 2020-5945) to develop a clinically implementable screening test -DovEEgene: developing and validating a novel molecular test for the early diagnosis of cancer of the endometrium, tubes and ovaries. This study is designed to identify endometrial, tubal and ovarian cancer very early based on identifying cancer-specific mutations (cancer DNA) in a pap sample taken from inside the uterus. The results are particularly encouraging given that control group is challenging with high background mutational burden from benign tumours, endometriosis, germ-line mutations etc.\n\nTo date, all the intrauterine samples were obtained using the commercially available TAO brush™ which is designed to take an endometrial sample. However, when patient tolerability was assessed using a numerical pain scale (NPS) ranging from 0 (no pain) to 10 (severe pain), patients rated the sampling using the TAO brush™ at 3.5 versus 0 for a cervical pap sample. These results were not surprising as the TAO brush™ was designed for dislodging strips of endometrial tissue to use for histopathologic examination. With respect to the investigators objective, which is to collect cancer cells that have exfoliated to the uterus, a sampler that collects these exfoliated cells with as little disturbance as possible to the underlying endometrium is preferred. In this sub-study, the investigators aim to evaluate a new endometrial sampling tool, the DOvEEgene Fleur, which is believe to be superior to the current TAO brush™ in terms of cancer detection, ease of use and patient tolerability. The sampler has been designed using materials\u002Fcomponents found in the TAO brush™ and other approved medical devices.",[545],"Women With Suspected or Confirmed Gynecological Disease",[547,548,549,550,551,552,553,554,555],"Ovarian Cancer","Endometrial Cancer","Genomics","DNA tagging","Somatic mutations","Endometrial sampling","Uterine sampling","Medical device","Uterine biofluid","2025-09-23",{"date":558,"type":42},"2025-09-26",{"date":560,"type":42},"2020-12-11",{"date":562,"type":23},"2026-10-01",{"name":48,"class":49},{"id":565,"slug":566,"hasResults":12,"nctId":567,"briefTitle":568,"officialTitle":569,"acronym":4,"eligibilityCriteria":570,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":322,"enrollmentInfo":571,"targetDuration":4,"studyType":24,"phases":573,"briefSummary":574,"conditions":575,"keywords":579,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":587,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":76},"100564129","perfectionism-and-daily-coping-and-emotion-regulation-processes-a-trial-of-two-explanatory-feedback-interventions-100564129","NCT06625151","Perfectionism and Daily Coping and Emotion Regulation Processes: A Trial of Two Explanatory Feedback Interventions","Perfectionism and Daily Stress, Coping, and Well-Being: Testing an Explanatory Feedback Intervention","Individuals potentially interested in participating will be prescreened for levels of SC perfectionism and negative and positive mood.\n\nInclusion Criteria:\n\n* Included in the study will be students who score 0.5 standard deviation above the mean score on two or more of four brief \\[4- or 5-item\\] measures of SC perfectionism (DEQ self-criticism, FMPS concern over mistakes, HMPS socially prescribed perfectionism, and APS-R discrepancy) for previous student samples\n\nExclusion Criteria:\n\n* Individuals who meet the criteria for a diagnosis of depression or anxiety disorders and who do not have concomitant mental health care will be excluded from the study.\n* Participants will be excluded if they fail to complete any of the Time 1 measures, or seven days of the daily diary procedure.",{"count":572,"type":23},200,[26],"Over the past three decades, perfectionism has received increasing theoretical and empirical attention as a cognitive-personality factor that increases vulnerability to a wide range of psychological problems, including depression and anxiety. Although mediators and moderators of the link between perfectionism and well-being have been identified, the direct clinical utility of these findings has not been a focus. The Perfectionism and Coping Processes Model - Explanatory Feedback Intervention (PCPM-EFI) draws on previous findings and individually analyzes participant responses to perfectionism measures and online daily questionnaires of stress, coping, and mood over 7 days. The EFI provides an individualized slideshow presentation that is delivered in a single 45-60 minute session by a student research assistant to address how stress and coping patterns trigger and maintain negative affect and (lower) positive affect in the participant's daily life. A recent waitlist controlled feasibility trial compared the PCPM-EFI condition with a waitlist control condition over 4 weeks in 176 university students with higher SC perfectionism, with individualized feedback delivered one-on-one by student trainees in-person or remotely through videoconferencing. The feasibility of the individualized analyses of each participant's daily data was supported by identifying daily trigger patterns, maintenance tendencies, strengths, common triggers, and best targets for reducing negative mood and increasing positive mood across several stressors for each participant. Participant ratings indicated that the comprehensive feedback was coherent and functional. Participants in the EFI condition, compared to those in the control condition, reported increases in empowerment, coping self-efficacy, and problem-focused coping, as well as decreases in depressive and anxious symptoms. Between-group effect sizes were moderate-to-large. There were reliable improvements in empowerment and depressive symptoms for 56% and 36%, respectively, of participants in the EFI condition. These findings demonstrate the broad applicability, conceptual utility, and effectiveness of the PCPM-EFI for self-critical perfectionistic individuals. Given these promising findings, research is needed to examine the utility of customizing daily emotion regulation findings, and the complementary effects of providing meaningful feedback on well-being.\n\nThe present study will build on the promising findings of the PCPM-EFI by using a 7-day daily diary methodology to test a complementary EFI on perfectionism and emotion regulation processes (e.g., self-compassion, mindfulness, experiential avoidance, rumination, reappraisal) delivered online through videoconferencing in a sample of university students with higher self-critical perfectionism. Based on the Perfectionism and Emotion Regulation Processes Model (PERPM), the PERPM-EFI follows the same structure as the PCPM-EFI to provide individualized analyses drawn from previous findings. The results of a pilot study of 12 university students with higher SC perfectionism suggest that the PERPM-EFI is broadly applicable, conceptually useful, and effective. Specifically, despite the small sample size, participants reported increases in empowerment, mindfulness, self-compassion, and emotional self-awareness, as well as decreases in depressive and anxious symptoms. The present study will use a randomized control design to examine whether the PCPM-EFI plus PERPM-EFI can better improve well-being, relative to providing no feedback, the PERPM-EFI alone, or PCPM-EFI alone in the context of a 4-week longitudinal study with three time points in a sample of 180 university students. The four conditions will be: (a) waitlist control condition, (b) PCPM-EFI, (c) PERPM-EFI, and (d) PCPM-EFI plus PERPM-EFI. It is hypothesized that all three EFI conditions will yield better outcomes than the waitlist control condition. It is also hypothesized that the combined PCPM-EFI plus PERPM-EFI condition will be superior to the PCPM-EFI condition and PERPM-EFI condition on empowerment (primary outcome) and secondary symptom outcomes (i.e., depressive symptoms, anxious symptoms, negative affect, positive affect). It is also expected that participants in the PCPM-EFI plus PERPM-EFI condition and PCPM-EFI condition will exhibit larger increases in coping self-efficacy and problem-focused coping than participants in the PERPM-EFI condition. On the other hand, it is hypothesized that participants in the PCPM-EFI plus PERPM-EFI condition and PERPM-EFI condition will exhibit larger increases in self-compassion, mindfulness, and emotional self-awareness than participants in the PCPM-EFI condition. If the feedback interventions are shown to be efficacious, the interventions could be offered to universities, work places, clinical settings, and other organizations.",[576,577,578],"Perfectionism","Psychological Well-being","University Students",[576,580,581,582,583,584,585],"Stress","Coping","Emotion Regulation","Mood","Daily Diary","Feedback Intervention","2025-09-22",{"date":556,"type":42},{"date":589,"type":42},"2024-10-23",{"date":591,"type":23},"2026-12",{"name":48,"class":49},{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":598,"acronym":4,"eligibilityCriteria":599,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":600,"targetDuration":4,"studyType":24,"phases":602,"briefSummary":603,"conditions":604,"keywords":607,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":586,"lastUpdatePostDateStruct":613,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":377},"100521437","implementation-of-support-in-the-care-of-adults-living-with-type-1-diabetes-100521437","NCT06069583","Implementation of Support in the Care of Adults Living With Type 1 Diabetes","Using the Support Online Platform for Self-management Education of Adults Living With Type 1 Diabetes as Part of Usual Care or Independently: an Implementation Study","Inclusion Criteria:\n\n* Diagnosis of T1D (including LADA - latent autoimmune diabetes in adults)\n* Have access to Internet\n* Use of an active email address\n* Comprehension of English or French\n* Live in Canada\n\nExclusion Criteria:\n\n\\- Unable to use the Support platform",{"count":601,"type":23},322,[26],"The investigators will conduct a trial to evaluate if an online training and support platform can help adults living with type 1 diabetes (T1D) in their diabetes self-management. Investigators will compare a group that has access to the \"Support\" platform through their usual medical care to a group that accesses the platform independently. The first group will be recruited through four participating clinics in the province of Quebec (Canada). The second group will be composed of adults living with T1D across Canada. Participants will have access to the platform for 12 months and will be asked to complete online questionnaires at the beginning and after 6 and 12 months, and share their glucose reader data with the research team. A subgroup of participants as well as healthcare professionals from the four clinics will be invited to participate in an individual interview aiming to understand the barriers and facilitators of integration \"Support\" in clinical care.",[498,605,500,499,606],"Metabolic Disease","Immune System Diseases",[608,609,610,611,612],"self-management education","Hemaglobin A1c","Online education","adults","type 1 diabetes",{"date":614,"type":42},"2025-09-25",{"date":616,"type":42},"2024-05-05",{"date":618,"type":23},"2027-10",{"name":48,"class":49},{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":625,"acronym":626,"eligibilityCriteria":627,"healthyVolunteers":12,"sex":18,"minAge":58,"maxAge":4,"enrollmentInfo":628,"targetDuration":630,"studyType":61,"phases":4,"briefSummary":631,"conditions":632,"keywords":635,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":644,"lastUpdatePostDateStruct":645,"startDateStruct":647,"completionDateStruct":649,"leadSponsor":651,"locationsCount":142},"100600261","scaling-up-point-of-care-hepatitis-c-testing-and-treatment-in-canada-100600261","NCT07095192","Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada","Scaling Up Point-of-Care Hepatitis C Testing and Treatment in Canada: A Multilevel Implementation Science Study of Clinical Processes, Barriers, Facilitators and Implementation Strategies","SCALE POCT","Inclusion Criteria:\n\n* Individuals aged ≥18 years who have a risk factor for HCV acquisition or are attending a site that provides services to people with an HCV acquisition risk.\n* Service providers and managers who are currently employed at a site providing HCV-related services, involved in or supervising the delivery of HCV-related services.\n* Policymaker must hold a position in local, provincial, or national government or a health authority that influences HCV testing\u002Ftreatment policies and be able to provide insights into the strategic planning and funding for HCV care.\n* Laboratory and quality assurance stakeholders must hold a role in laboratory services, quality assurance, or regulatory oversight of point-of-care testing at the provincial, national, or organizational level.\n\nExclusion Criteria:\n\n* Younger than 18 years old",{"count":629,"type":23},300,"1 Month","The SCALE-POCT study is a national initiative designed to provide robust evidence for scaling up point-of-care hepatitis C testing for key populations. The study seeks to map current hepatitis C clinical processes, identify barriers and facilitators to implementation, and co-design practical tools and strategies in partnership with stakeholders.\n\nA major obstacle to hepatitis C elimination and increasing treatment uptake is the current multi-step diagnostic process, which leads to loss to follow-up and treatment delays, particularly among high-risk groups such as people who inject drugs. Point of-care hepatitis C antibody tests (results: 5-20 mins) and RNA tests (results: 60 mins), could enable single-visit diagnosis, reducing loss to follow-up. However, integrating these tests into key settings presents challenges. The overarching goal of this study is to generate evidence to inform the scale-up point-of-care hepatitis C testing and treatment in key settings in Canada. This study is observational in nature and does not involve the direct implementation of point-of-care hepatitis C testing. Instead, it aims to understand the contextual, procedural, and operational factors that would support its successful adoption and sustainability. By examining existing care models and engaging with key stakeholders, the study seeks to build a foundation for future implementation efforts. Specific objectives include:\n\n1. Map current hepatitis C care processes and explore how point-of-care testing could fit into these models;\n2. Identify barriers and facilitators to implementing point-of-care hepatitis C testing across settings and provinces;\n3. Co-design tools and strategies (such as training guides, standard procedures) to support point-of-care testing;\n4. Assess feasibility, acceptability, and costs of the co-designed tools and strategies.",[633,634],"HCV","HEPATITIS C VIRUS CHRONIC INFECTION",[633,636,637,638,639,640,641,642,643],"Hepatitis C Virus Chronic Infection","Rapid point-of-care testing","Implementation science","Knowledge translation","Marginalized populations","Infectious diseases","Barriers and facilitators","Implementation strategies","2025-07-23",{"date":646,"type":42},"2025-07-31",{"date":648,"type":42},"2025-05-20",{"date":650,"type":23},"2028-09-20",{"name":48,"class":49},{"id":653,"slug":654,"hasResults":12,"nctId":655,"briefTitle":656,"officialTitle":656,"acronym":4,"eligibilityCriteria":657,"healthyVolunteers":12,"sex":18,"minAge":658,"maxAge":322,"enrollmentInfo":659,"targetDuration":4,"studyType":24,"phases":661,"briefSummary":662,"conditions":663,"keywords":665,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":669,"lastUpdatePostDateStruct":670,"startDateStruct":672,"completionDateStruct":674,"leadSponsor":676,"locationsCount":76},"100598531","feasibility-and-acceptability-of-an-evidence-informed-virtual-intervention-to-reduce-perceptions-of-injustice-following-work-injury-100598531","NCT07072702","Feasibility and Acceptability of an Evidence-Informed Virtual Intervention to Reduce Perceptions of Injustice Following Work Injury","Inclusion Criteria:\n\n1. working knowledge of English,\n2. work absence of less than 8 weeks duration following a musculoskeletal injury to the back or neck,\n3. a score above clinical threshold on a self-report measure of perceived injustice,\n4. between 25 and 65 years of age,\n5. referred for primary care physiotherapy, and\n6. currently receiving wage indemnity benefits from the WSIB.\n\nExclusion Criteria:\n\n1. currently receiving psychological services for a mental health problem,\n2. clinical evidence of vertebral fracture, disk herniation, infectious disease, or rheumatoid arthritis (determined from referral information),\n3. illiteracy or severe cognitive impairment (determined informally through the intake interview).","25 Years",{"count":660,"type":23},75,[26],"Many individuals who have sustained disabling injuries in the workplace react to their situation with a sense of 'injustice'. Research over the past 20 years has revealed that, interpreting one's post-injury life situation as 'unjust', actually interferes with recovery from the disabling injury. Post-injury perceptions of injustice contribute to more severe pain, more severe symptoms of depression and PTSD, and more prolonged absence from work. Several clinical researchers have highlighted the need to develop approaches to treatment that can reduce post-injury perceptions of injustice.\n\nA brief intervention was developed to reduce post-injury perceptions of injustice. The intervention consists of 4 30-minute sessions with a psychologist. The intervention is called 'Managing Post-Injury Challenges' (MPIC). The MPIC sessions are delivered virtually (online). As a first step toward determining whether MPIC has added value for promoting more successful recovery following work injury, the proposed research will assess the feasibility of MPIC. Some of the feasibility questions that will be addressed include: Are injured workers interested in participating in MPIC? Do injured individuals remain sufficiently engaged to complete all 4 sessions of MPIC? Does participation in MPIC contribute to meaningful reductions in perceived injustice? And are injured individuals satisfied with the benefits of MPIC?\n\nMPIC differs from many other rehabilitation interventions in that it focuses on a 'risk-factor' for problematic recovery as opposed to treating a specific health or mental health problem. At this time, there is little information about whether injured workers are interested in interventions focusing on 'risk factors' for problematic recovery. As a first step in evaluating the effectiveness of MPIC, it is necessary to demonstrate that MPIC is acceptable to injured workers. We would consider the study to be successful if 1) at least 75% of eligible injured workers agree to enrol in MPIC, 2) if at least 75% of participants attend all 4 sessions of MPIC, and if at least 75% of participants are satisfied with the benefits they derived from their involvement in MPIC. If MPIC is ultimately shown to be effective in reducing post-injury perceptions of injustice, offering MPIC to injured workers with elevated scores on a measure of perceived injustice could contribute to more successful recovery.",[664],"MSK Conditions",[299,666,667,668],"Disability","Psychosocial","Perceived Injustice","2025-07-17",{"date":671,"type":42},"2025-07-18",{"date":673,"type":42},"2024-09-30",{"date":675,"type":23},"2026-06-30",{"name":48,"class":49},{"id":678,"slug":679,"hasResults":12,"nctId":680,"briefTitle":681,"officialTitle":682,"acronym":4,"eligibilityCriteria":683,"healthyVolunteers":57,"sex":176,"minAge":684,"maxAge":210,"enrollmentInfo":685,"targetDuration":4,"studyType":24,"phases":687,"briefSummary":688,"conditions":689,"keywords":691,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":694,"lastUpdatePostDateStruct":695,"startDateStruct":697,"completionDateStruct":699,"leadSponsor":701,"locationsCount":50},"100430895","early-detection-of-endometrialovarian-cancer-and-hereditary-predisposition-of-these-cancers-100430895","NCT04891029","Early Detection of Endometrial\u002FOvarian Cancer and Hereditary Predisposition of These Cancers","Phase III Diagnostic Trial for Early Detection of Endometrial\u002FOvarian Cancer and Hereditary Predisposition of These Cancers","Inclusion Criteria:\n\n\\- Capacity to understand study and provide informed consent\n\nExclusion Criteria:\n\n* Prior hysterectomy\n* Be pregnant\n* Be nursing\n* Be undergoing any fertility treatment\n* Have had recent history of uterine perforation","45 Years",{"count":686,"type":23},5600,[26],"Early stage high-grade cancer, endometrial and ovarian, has few, if any, symptoms or signs. When symptoms appear, the disease is commonly in advanced stage meaning it has left the gynaecological organs and metastasized to the pelvic\u002Fabdominal cavity. The McGill research group had showed in the DOvEE trial (NCT02296307), that fast-track assessment with transvaginal ultrasound scans (TVUS) and serial CA125 of women with vague symptoms associated with ovarian and endometrial cancer did diagnose these cancers earlier in the disease trajectory, with low-volume resectable disease, but only after the cancer had already become Stage III. One way to detect these cancers earlier is to screen asymptomatic women. Unfortunately, none of the currently available tests, including TVUS and CA-125 have been shown to be useful for screening for ovarian or endometrial cancer.\n\nThe McGill team has developed a genomic assay to screen and detect these cancers earlier in the trajectory than is currently the case. The test identifies pathogenic somatic mutations (necessary early steps in the development of these cancers), in an uterine cytological sample. It is able to do so by incorporating a machine-learning derived classifier that can discriminate the mutational signature of these cancers from benign disease with a sensitivity of 80% and a specificity of 100% in a healthy population of peri- and post-menopausal women. In addition to the uterine sample, the test includes a saliva sample that acts as an internal control but can also identify germline pathogenic variants that predispose to hereditary endometrial\u002Fovarian cancers as well as breast, pancreas, and colon cancers.\n\nThe test was developed in a retrospective population in whom the assay was done pre-operatively and the diagnosis of malignancy versus benign gynecological disease was confirmed by detailed pathological analysis of the uterus, tubes, and ovaries after surgical resection (NCT02288676). The test is now ready to be tested as a phase III diagnostic test in the general population to see if these results are just as promising in the community at large.",[690],"Diagnoses Disease",[547,548,549,692,693],"Screening","Early detection","2025-06-13",{"date":696,"type":42},"2025-06-17",{"date":698,"type":42},"2021-05-10",{"date":700,"type":23},"2028-11",{"name":48,"class":49},{"id":703,"slug":704,"hasResults":12,"nctId":705,"briefTitle":706,"officialTitle":706,"acronym":707,"eligibilityCriteria":708,"healthyVolunteers":12,"sex":176,"minAge":58,"maxAge":4,"enrollmentInfo":709,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":711,"conditions":712,"keywords":719,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":694,"lastUpdatePostDateStruct":726,"startDateStruct":728,"completionDateStruct":730,"leadSponsor":732,"locationsCount":76},"100231289","doveegenewise-genomics-diagnosing-ovarian-and-endometrial-cancer-early-using-genomics-100231289","NCT02288676","DOvEEgene\u002FWISE Genomics: Diagnosing Ovarian and Endometrial Cancer Early Using Genomics","DOvEEgene","Case Inclusion:\n\n* Subjects should have suspected or confirmed cancer of the upper genital tract.\n* Participant will undergo surgery for tumour removal.\n\nControl inclusion:\n\n• Subjects should be scheduled to have a hysterectomy, bilateral salpingectomy, with or without bilateral oophorectomy, for presumed benign disease.",{"count":710,"type":23},1200,"This study aims to develop and validate a test for detecting ovarian and endometrial cancers early. It relies on detecting somatic mutations that are associated with these cancers from a uterine pap test. A saliva sample is also collected that acts as an internal control and has the ability to detect deleterious germline mutations associated with common hereditary cancers (such as breast, ovarian, endometrial, colon, and pancreatic cancers). A machine learning classifier is then used to discriminate between cancer and benign disease.",[713,714,548,547,692,715,716,717,718],"Ovarian Neoplasms","Endometrial Neoplasms","Safety","Reduced Mortality","Reduced Morbidity","Early Diagnosis",[720,721,722,723,724,725,550],"genomics","somatic mutations","genetic mutations","high-grade serous cancer","ovarian cancer","endometrial cancer",{"date":727,"type":42},"2025-06-18",{"date":729,"type":42},"2014-01",{"date":731,"type":23},"2026-10",{"name":48,"class":49},""]